OR WAIT null SECS
PharmaNet Development Group, announced that it is collaborating with the Cancer Immunotherapy Trials Network (CITN) in order to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.
"We are thrilled to collaborate with the Cancer Immunotherapy Trials Network multi-investigator team," commented Anthony Maida, PhD, MA, MBA, Vice President, Clinical Research and General Manager, Oncology. "The association allows us to identify oncology centers of excellence and thought leadersto collaborate on the development of cutting-edge therapeutics."
PharmaNet has been conducting clinical studies for oncology products since 1996 and has a team that includes on-staff oncologists, dedicated to the development of cancer treatments. The Company has experience in the development of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types. Two hundred local, regional and global oncology clinical trials have been awarded to PharmaNet in the past five years, including eleven registration programs, seven which resulted in NDA/MAA approvals.